CliffBio
biologic

Infanrix

Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed

Loss of exclusivityJanuary 2009projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameInfanrix
Active ingredientDiphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
Strength25LF/10LF/25UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 1997
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Infanrix patent cliff — loss of exclusivity January 2009 | CliffBio